369 related articles for article (PubMed ID: 31829234)
21. Clinical trials integrity: a CRO perspective.
Beach JE
Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
[TBL] [Abstract][Full Text] [Related]
22. Learning from OCTET - exploring the acceptability of clinical trials management methods.
Arundel C; Gellatly J
Trials; 2018 Jul; 19(1):378. PubMed ID: 30005659
[TBL] [Abstract][Full Text] [Related]
23. [The roles and responsibilities of the pharmaceutical industry].
Dejgaard A; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1676-9. PubMed ID: 12756829
[TBL] [Abstract][Full Text] [Related]
24. Conflict of interest in clinical research: direct payment to the investigators for finding human subjects and health information.
Puttagunta PS; Caulfield TA; Griener G
Health Law Rev; 2002; 10(2):30-2. PubMed ID: 15739309
[TBL] [Abstract][Full Text] [Related]
25. Biopharmaceutical industry-sponsored global clinical trials in emerging countries.
Alvarenga LS; Martins EN
Rev Assoc Med Bras (1992); 2010; 56(4):428-33. PubMed ID: 20835639
[TBL] [Abstract][Full Text] [Related]
26. Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
Walter E; Eichhober G; Voit M; Baumgartner C; Celedin A; Holzhauser C; Mraz B; Ornauer C; Pleiner-Duxneuner J; Ponner B; Presch I; Pum G; Tieben H; Weingartmann G; Baltic D; Bonitz W; Kaehler ST
J Med Econ; 2020 Jun; 23(6):566-574. PubMed ID: 32046538
[No Abstract] [Full Text] [Related]
27. Conflicts of interest in research involving human beings.
Greco D; Diniz NM
J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
[TBL] [Abstract][Full Text] [Related]
28. Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study.
Jones CW; Misemer BS; Platts-Mills TF; Ahn R; Woodbridge A; Abraham A; Saba S; Korenstein D; Madden E; Keyhani S
BMJ Open; 2018 Feb; 8(2):e019831. PubMed ID: 29439079
[TBL] [Abstract][Full Text] [Related]
29. Joint recommendations for a total services account as a factor in simplifying contracts.
Bruns I; Schade-Brittinger C; Wissing F; Ruppert T; Trillsch M
Ger Med Sci; 2019; 17():Doc10. PubMed ID: 31728135
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
31. Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics.
Campbell MJ
Pharm Stat; 2011; 10(1):80-1. PubMed ID: 21275038
[No Abstract] [Full Text] [Related]
32. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases.
Stein S; Bogard E; Boice N; Fernandez V; Field T; Gilstrap A; Kahn SR; Larkindale J; Mathieson T
Orphanet J Rare Dis; 2018 Jan; 13(1):18. PubMed ID: 29357903
[TBL] [Abstract][Full Text] [Related]
33. Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.
Baronikova S; Purvis J; Southam E; Beeso J; Panayi A; Winchester C
BMJ Evid Based Med; 2019 Oct; 24(5):177-184. PubMed ID: 30898790
[TBL] [Abstract][Full Text] [Related]
34. Boost bottom line with research nurse.
ED Manag; 2001 Dec; 13(12):140-2. PubMed ID: 11769137
[TBL] [Abstract][Full Text] [Related]
35. Industry sponsorship and selection of comparators in randomized clinical trials.
Lathyris DN; Patsopoulos NA; Salanti G; Ioannidis JP
Eur J Clin Invest; 2010 Feb; 40(2):172-82. PubMed ID: 20050879
[TBL] [Abstract][Full Text] [Related]
36. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience.
Henry DA; Kerridge IH; Hill SR; McNeill PM; Doran E; Newby DA; Henderson KM; Maguire J; Stokes BJ; Macdonald GJ; Day RO
Med J Aust; 2005 Jun; 182(11):557-60. PubMed ID: 15938681
[TBL] [Abstract][Full Text] [Related]
37. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.
Heres S; Davis J; Maino K; Jetzinger E; Kissling W; Leucht S
Am J Psychiatry; 2006 Feb; 163(2):185-94. PubMed ID: 16449469
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
Russ H; Busta S; Jost B; Bethke TD
Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
[TBL] [Abstract][Full Text] [Related]
39. Key cost drivers of pharmaceutical clinical trials in the United States.
Sertkaya A; Wong HH; Jessup A; Beleche T
Clin Trials; 2016 Apr; 13(2):117-26. PubMed ID: 26908540
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
